Drooling in Parkinson ’s Disease: Evidence of a Role for Divided Attention
This study assessed whether frequency of saliva swallows reduced, and drooling severity and frequency increased, when people with PD engaged in a cognitively distracting task. 18 patients with idiopathic PD reporting daytime dro oling on the Unified Parkinson’s Disease Rating Scale (UPDRS) were recruited. They completed the Radboud Oral Motor Inventory for PD saliva questionnaire and the Montreal Cognitive Assessment. UPDRS drooling score, disease stage, duration, gender, and age were recorded. Swallow frequency and drool ing severity and frequency were measured at rest and during a distracting computer-based language task. There was no significant difference between drooling severity at rest and during distraction (Wilcoxon signed rank testz = − 1.724,p = 0.085). There was a significant difference between at rest and distraction conditions for both drooling frequency (Wilcoxon signed rank testz = − 2.041,p = 0.041) and swallow frequency (Wilcoxon signed rank testz = − 3.054,p = 0.002). Participants swallowed less frequently and drooled more often during the distraction task. The frequency of saliva swallows and drooling are affected by divided attention in a dual-task paradigm. Further studies are needed to explore the exact role of attention in saliva management an d the clinical applications in assessment and treatment.
Ruwani S. Wijeyekoon, Deborah Kronenberg-Versteeg, Kirsten M. Scott, Shaista Hayat, Joanne L. Jones, Menna R. Clatworthy, R. Andres Floto, Roger A. Barker, Caroline H. Williams-Gray
PARKINSON ’S disease symptoms develop slowly over a long period of time, and could be caused by nerve damage in the brain. These are the most common warning signs and symptoms of the neurodegenerative condition - can you hear this sound in your voice when you talk?
Condition: Parkinson Disease Intervention: Sponsors: Rush University Medical Center; California Institute of Technology; Purdue University Recruiting
Paulina Troncoso-Escudero, Alejandra Parra, Melissa Nassif, Rene L. Vidal
Authors: Altimus CM, Keller K, Brannelly P, Ross E, Lin CT, Riley EAU, Briggs L, Smith J, Stevens M Abstract Neurodegenerative diseases encompass a range of diagnoses, such as Alzheimer's disease and Parkinson's disease. Despite decades of advancements in understanding the neurobiology of individual diseases, this class has few disease-modifying therapeutics and a paucity of biomarkers for diagnosis or progression. However, tau protein aggregation has emerged as a potential unifying factor across several neurodegenerative diseases, which has prompted a rapid growth in tau-related funding. In spite of this growth, r...
The pallidothalamic tract connects the globus pallidus internus and the ventrolateral portion of the thalamus, and ablation of the pallidothalamic tract (pallidothalamic tractotomy [PTT]) reportedly exerts antiparkinsonian effects. However, the detailed clinical course has not yet been elucidated. Here, we present the first single case report of PTT performed in a patient with Parkinson ’s disease, with 1-year follow-up.
Re-emergent tremor (RET) is a common form of postural tremor observed in Parkinson's disease (PD) patients. Recent studies have shown that administration of levodopa decreases RET amplitude. However, drug effects on tremor pause duration are less clear.
In this prospective longitudinal study, the relationship between white matter lesions (WML), manually delineated on MRI, and cognitive decline over a two-year period was examined in 34 patients with Parkinson's disease (PD). WML was associated with clinically important cognitive impairment in PD, i.e. the transition from normal cognition to mild cognitive impairment (MCI). (see Fig. 1)
AbstractPurpose of ReviewParkinson ’s disease was studied for a long time from the prism of a motor impairment. Recent advances have outlined the importance of cognitive and neuropsychiatric symptoms (NPS) in the PD equation. This review concentrates on the present possibilities of using neuroimaging techniques in order to quantify the cognitive performance and NPS in PD patients.Recent FindingsMild cognitive impairment as well as many NPS have been acknowledged as important criteria for assessing the quality of life in patients with Parkinson ’s disease and have been shown as potential factors in predicting fu...
AbstractEnd-of-dose motor fluctuations are regarded as one of the core troublesome symptoms by patients with Parkinson ’s disease (PD). Treatment of levodopa (l-dopa)-induced motor fluctuations is still an unmet medical need.l-dopa is the gold standard in the treatment of motor PD symptoms; notwithstanding, a wide range of adjunct therapies are currently available for the treatment of end-of-dose motor fluctuations. Additionally, device-aided therapies, such as deep brain stimulation,l-dopa-carbidopa intestinal gel infusion, and on-demand injection or continuous apomorphine infusion, may be considered when oral treat...